Catching Element Formation In The Act

Gamma-ray astronomy explores the most energetic photons in nature to address some of the most pressing puzzles in contemporary astrophysics. It encompasses a wide range of objects and phenomena: stars, supernovae, novae, neutron stars, stellar-mass black holes, nucleosynthesis, the interstellar medium, cosmic rays and relativistic-particle acceleration, and the evolution of galaxies. MeV gamma-rays provide a unique probe of nuclear processes in astronomy, directly measuring radioactive decay, nuclear de-excitation, and positron annihilation. The substantial information carried by gamma-ray photons allows us to see deeper into these objects, the bulk of the power is often emitted at gamma-ray energies, and radioactivity provides a natural physical clock that adds unique information. New science will be driven by time-domain population studies at gamma-ray energies. This science is enabled by next-generation gamma-ray instruments with one to two orders of magnitude better sensitivity, larger sky coverage, and faster cadence than all previous gamma-ray instruments. This transformative capability permits: (a) the accurate identification of the gamma-ray emitting objects and correlations with observations taken at other wavelengths and with other messengers; (b) construction of new gamma-ray maps of the Milky Way and other nearby galaxies where extended regions are distinguished from point sources; and (c) considerable serendipitous science of scarce events -- nearby neutron star mergers, for example. Advances in technology push the performance of new gamma-ray instruments to address a wide set of astrophysical questions.Comment: 14 pages including 3 figure

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Assessing Gharats of the Kamand Valley

This project assessed the challenges facing traditional Himalayan watermills known as gharats. We conducted site assessments at 21 gharats and interviewed both mill owners and local grain farmers to explore the social, technical, economic, and environmental reasons for mill abandonment. Additionally, we examined the factors causing diminishing demand for gharats’ services. We developed recommendations for watermill owners, and initiated a pilot renovation on an abandoned mill to test innovations that can maintain the gharat’s tradition

Design and Optimization of a Micro-Aerial Vehicle

AIAA’s 2016 Design/Build/Fly Competition required the construction of two separate systems to complete distributive manufacturing missions. The team had to develop a production aircraft to carry a 1 kg payload and a manufacturing support aircraft which could carry the production aircraft internally. Aircraft designs were finalized using merit analyses and iterative design techniques to make quantitative decisions. The team selected a flying wing design for the production aircraft nested inside the wing of a conventional design manufacturing support aircraft as final configurations. The aircraft were manufactured and tested to ensure designs would complete mission requirements while maintaining the highest possible score by retaining minimal components and a low aircraft weight

Loss of the Martian atmosphere to space: Present-day loss rates determined from MAVEN observations and integrated loss through time

International audienceObservations of the Mars upper atmosphere made from the Mars Atmosphere and Volatile Evolution (MAVEN) spacecraft have been used to determine the loss rates of gas from the upper atmosphere to space for a complete Mars year (16 Nov 2014 – 3 Oct 2016). Loss rates for H and O are sufficient to remove ∼2-3 kg/s to space. By itself, this loss would be significant over the history of the planet. In addition, loss rates would have been greater early in history due to the enhanced solar EUV and more-active Sun. Integrated loss, based on current processes whose escape rates in the past are adjusted according to expected solar evolution, would have been as much as 0.8 bar CO2 or 23 m global equivalent layer of H2O; these losses are likely to be lower limits due to the nature of the extrapolation of loss rates to the earliest times. Combined with the lack of surface or subsurface reservoirs for CO2 that could hold remnants of an early, thick atmosphere, these results suggest that loss of gas to space has been the dominant process responsible for changing the climate of Mars from an early, warmer environment to the cold, dry one that we see today